US Sets 0% Tariff on Rare Disease, Specialty Drugs From India
The US has established a zero percent tariff on certain specialty drugs from India, effective September 29, amid a 100% tariff on patented medicines. This includes drugs for rare diseases and fertility treatments.
What Happened?
The US has established a zero percent tariff on certain specialty drugs from India, effective September 29, amid a 100% tariff on patented medicines. This includes drugs for rare diseases and fertility treatments.
AI Quick Summary
The US has set a 0% tariff on certain specialty drugs from India, effective September 29, while imposing a 100% tariff on patented medicines.
Key points
- The US will not charge tariffs on certain specialty drugs from India.
- This includes drugs for rare diseases, fertility treatments, and gene therapies.
- A 100% tariff on certain patented medicines from India will take effect on September 29.
- The zero tariff applies to drugs from India and 19 other countries.
- Generic pharmaceutical products are currently exempt from the new tariff.
Key insights
- The zero tariff may enhance competitiveness for Indian specialty drug manufacturers.
- Indian firms could face tariff pressure on patented drugs not covered by the exemption.
- The US Commerce Secretary may review the exemption for generics within a year.
Impact on India
The zero tariff on specialty drugs may positively influence Indian pharmaceutical exports to the US.
Why it matters
The US is a major market for Indian pharmaceuticals, and the zero tariff could benefit Indian firms producing specialty drugs.
Entities
Source
Times Now
